卡培他滨联合伊立替康二线治疗复发转移性结直肠癌的临床研究  

Clinical study of capecitabine and irinotecan for second-line treatment of recurrent metastatic colorectal cancer

作　　者：熊勇 李小兵 杨灵 邹瑜斌 徐满珍 

机构地区：[1]江西省新余市人民医院肿瘤科,江西新余338000

出　　处：《中国当代医药》2013年第29期86-87,共2页China Modern Medicine

摘　　要：目的 研究卡培他滨联合伊立替康二线治疗复发转移性结直肠癌的临床效果.方法 将本院2010年5月～2013年2月收治的90例复发转移性结直肠癌患者随机分为观察组（n=45）和对照组（n=45）,观察组患者采用卡培他滨联合伊立替康治疗,对照组患者采用伊立替康治疗.结果 观察组患者近期有效率为55.56％,临床获益率为80.00％;对照组患者近期有效率为33.33％,临床获益率为64.44％,观察组患者的近期有效率和临床获益率均显著优于对照组（P＜0.05）,两组患者的不良反应差异无统计学意义（P＞0.05）.结论 卡培他滨联合伊立替康二线治疗复发转移性结直肠癌的疗效确切,不良反应轻,值得临床推广应用.Objective To study the effect of capecitabine and irinotecan fi）r treatment of recurrent metastatic co]orectal cancer. Methods 90 patients with recurrent metastatic colorectal cancer in our hospital from May 2010 to February 2013 were randomly divided into observation group （n - 45） and control group （n = 45）.Observation group was given low-dose eapecitabine and irinotecan therapy and control group was given irinotecan therapy, Results The short-term efficacy of treatment was 55.56% ,disease control rate was 80.00% in observation group.The short-term efficacy of treatment was 33.33%,disease control rate was 64.44% in observation group.The short-term efficacy of treatment and disease control rate in the observation group were significant better than those in the control group （P〈0.05）.Moreover, there was no significant difference in untoward effect between two groups （P〉0.05）. Conclusion The capecitabine and irinotecan for treatment of recurrent metastatic colorectal cancer is efficacy,and has few untoward effect. It is worthy to be popularized.

关 键 词：卡培他滨 伊立替康 复发转移性结直肠癌 

分 类 号：R735.3[医药卫生—肿瘤]